Skip to main content
Terug
Watch Compare

Lineage Cell Therapeutics, Inc.

Datakwaliteit: 100%
LCTX
NYSE Manufacturing Chemicals
€ 1,48
▼ € 0,01 (-0,67%)
Marktkapitalisatie: 368,65 M
Prijs
€ 1,48
Marktkapitalisatie
368,65 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 35,32% annually over 5 years — strong growth
Negative free cash flow of -19,44 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 17,92%
Capital efficient — spends only 3,59% of revenue on capex

Groei

Revenue Growth (5Y)
35,32%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)53,24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-180,43%
Onder sectorgemiddelde (-53,53%)
ROIC-36,09%
Net Margin-436,47%
Op. Margin-251,57%

Veiligheid

Debt / Equity
N/A
Current Ratio4,50
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-5,80 | -19,10
Onder sectorgemiddelde (-1,48)
P/B Ratio16,73
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -5,8 -1,5
P/B 16,7 1,6
ROE % -180,4 -53,5
Net Margin % -436,5 -41,5
Rev Growth 5Y % 35,3 1,8
D/E — 0,3

Koersdoel Analisten

6 analisten
Buy
Huidig
€ 1,48
+204.1%
Koersdoel
€ 4,50
€ 3,00
€ 3,50
€ 9,00
Vooruitzicht
Forward K/W -19,10
Forward WPA -€ 0,08
Omzet Sch. 21,36 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,08
-€ 0,14 – € 0,02
 21,36 M 4
FY2026 -€ 0,06
-€ 0,14 – € 0,04
 25,63 M 4

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,04 € 0,00 +100,0%
Q32025 -€ 0,03 -€ 0,13 -358,9%
Q22025 -€ 0,03 -€ 0,13 -358,9%
Q12025 -€ 0,03 -€ 0,02 +28,6%

ETFs Holding This Stock

BRSIX BRSIX
0,08% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 53,24% Revenue Growth (3Y) 27,56%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 35,32% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 14,56 M Net Income (TTM) -63,53 M
ROE -180,43% ROA -70,42%
Gross Margin N/A Operating Margin -251,57%
Net Margin -436,47% Free Cash Flow (TTM) -19,44 M
ROIC -36,09% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,50
Interest Coverage N/A Asset Turnover 0,16
Working Capital 32,88 M Tangible Book Value -20,33 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5,80 Forward P/E -19,10
P/B Ratio 16,73 P/S Ratio 25,33
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 17,26 Fwd Earnings Yield N/A
FCF Yield -5,27%
Market Cap 368,65 M Enterprise Value 328,19 M
Per Share
EPS (Diluted TTM) -0,28 Revenue / Share 0,06
FCF / Share -0,08 OCF / Share -0,08
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 3,59% FCF Conversion 30,60%
SBC-Adj. FCF -24,43 M Growth Momentum 17,92

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 14,56 M 9,50 M 8,95 M 14,70 M 4,34 M
Net Income -63,53 M -18,61 M -21,49 M -26,27 M -43,02 M
EPS (Diluted) -0,28 -0,09 -0,12 — —
Gross Profit — — 8,27 M 13,98 M 2,92 M
Operating Income -36,62 M -21,48 M -24,73 M -22,52 M -49,21 M
EBITDA — — — — —
R&D Expenses 17,73 M 12,47 M 15,71 M 13,99 M 33,91 M
SG&A Expenses — — — — —
D&A 699.000,0 587.000,0 562.000,0 582.000,0 663.000,0
Interest Expense — — — 829.000,0 2.000,0
Income Tax -5,28 M 0,0 -1,80 M 541.000,0 -1,24 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 112,58 M 113,22 M 101,02 M 123,66 M 174,55 M
Total Liabilities 69,24 M 36,21 M 39,00 M 51,73 M 83,65 M
Shareholders' Equity 44,55 M 78,38 M 63,42 M 73,34 M 92,22 M
Total Debt — — — — —
Cash & Equivalents 40,79 M 45,79 M 35,44 M 11,36 M 55,74 M
Current Assets 59,16 M 51,00 M 38,44 M 60,00 M 111,55 M
Current Liabilities 11,37 M 13,98 M 17,96 M 18,98 M 47,12 M